Japan To Quadruple Order Of Relenza To Back Up H1N1 Flu Treatments
This article was originally published in PharmAsia News
Executive SummaryJapan is in line to receive four times the amount of GlaxoSmithKline's Relenza (zanamivir) it had received a year ago to serve as a treatment against the H1N1 and other strains of influenza. GSK's Japanese subsidiary said it would import the additional doses of the inhalation powder from U.K.-based GSK's plant in France. In addition to the GSK supply, Japan's Chugai Pharmaceutical, a unit of Swiss-based Roche, plans to triple its supply of Tamiflu (oseltamivir), covering up to 12 million people against the flu. (Click here for more - a subscription may be required
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.